BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) ends collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The company remains focused on providing value to the spatial biology community, expanding the capabilities of RNAscope technology and accelerating the development of a fully automated spatial multiomics workflow on the Lunaphore COMET™ system.

Positive

• Bio-Techne is committed to providing value to the spatial biology community by expanding the capabilities of RNAscope technology and developing a fully automated spatial multiomics workflow on the Lunaphore COMET™ system.

Negative

• None.

MINNEAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that the company will end their collaboration with Akoya Biosciences to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System. The decision was made following best efforts to achieve the intended program goals.

"Bio-Techne remains focused on providing the greatest value to the spatial biology community," said Kim Kelderman, President of Bio-Techne's Diagnostics and Genomics Segment. "We are actively expanding the capabilities of our gold-standard RNAscope technology to enable greater utility in multiomic spatial applications and plan to accelerate the development and commercialization of the first fully automated and scalable spatial multiomics workflow on the Lunaphore COMET™ system."

Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya.

About Bio-Techne Corporation

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
David.clair@bio-techne.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-ends-collaboration-program-with-akoya-to-automate-rnascope-on-the-phenocycler-fusion-301899458.html

SOURCE Bio-Techne Corporation

FAQ

What is the ticker symbol for Bio-Techne?

The ticker symbol for Bio-Techne is NASDAQ: TECH.

What is Bio-Techne ending their collaboration with Akoya Biosciences for?

Bio-Techne is ending their collaboration to co-develop an automated RNAscope™ workflow for use with the PhenoCycler®-Fusion System.

What technology is Bio-Techne planning to develop a fully automated spatial multiomics workflow on?

Bio-Techne plans to develop a fully automated spatial multiomics workflow on the Lunaphore COMET™ system.

What products will Bio-Techne continue to support for its customers?

Bio-Techne will continue to support its customers utilizing RNAscope assays in conjunction with Opal™ reagents and PhenoImager™ HT systems purchased from Akoya.